Next Article in Journal
Reversible Platelet Aggregation Induced by Low-Temperature Storage in Heparinized Whole Blood Samples
Previous Article in Journal
A Drop of Blood to Lead the Way
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 17
Issue 4
10.3390/hematolrep17040041
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Advantages of FVIII-Extended Half-Life (Turoctocog Alfa Pegol) in the Management of Cardiac Surgery in a Patient with Mild Hemophilia A: A Case Report and Literature Review

by
Angela Napolitano
1,
Andrea Venturini
2,
Mauro Ronzoni
2,
Graziella Saggiorato
1,
Paolo Simioni
1 and
Ezio Zanon
1,*
1
First Chair of Internal Medicine, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy
2
Cardiac Surgery Unit, Spedali Civili Hospital, University of Brescia, 25123 Brescia, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2025, 17(4), 41; https://doi.org/10.3390/hematolrep17040041
Submission received: 29 May 2025 / Revised: 25 July 2025 / Accepted: 30 July 2025 / Published: 6 August 2025
Browse Figures
Versions Notes

Abstract

Background and Clinical Significance: Hemophilia A presents a considerable challenge in cardiac surgery due to the elevated risk of perioperative bleeding, particularly during procedures involving cardiopulmonary bypass. Standard management typically involves standard half-life (SHL) factor VIII (FVIII) concentrates, which require frequent dosing. Extended half-life (EHL) FVIII products offer theoretical advantages, including prolonged action and reduced infusion frequency, but their use in cardiac surgery remains largely undocumented. Case Presentation: We report the case of a 73-year-old male with mild Hemophilia A who underwent successful aortic valve replacement using a 25 mm Carpentier-Edwards Magna Ease biological prosthesis. The patient was managed perioperatively with an anti-hemorrhagic protocol based on EHL recombinant FVIII. The surgery and postoperative course were uneventful, with no bleeding complications or need for transfusion. Conclusions: This case illustrates the potential role of EHL FVIII in safely managing hemophilic patients undergoing major cardiac surgery. Given the lack of existing reports in the literature, further studies are warranted to evaluate the efficacy and safety of EHL FVIII in this setting and to potentially optimize perioperative care protocols for this patient population.
Keywords: Cardiac surgery; hemophilia; FVIII-EHL Cardiac surgery; hemophilia; FVIII-EHL

Share and Cite

MDPI and ACS Style

Napolitano, A.; Venturini, A.; Ronzoni, M.; Saggiorato, G.; Simioni, P.; Zanon, E. Advantages of FVIII-Extended Half-Life (Turoctocog Alfa Pegol) in the Management of Cardiac Surgery in a Patient with Mild Hemophilia A: A Case Report and Literature Review. Hematol. Rep. 2025, 17, 41. https://doi.org/10.3390/hematolrep17040041

AMA Style

Napolitano A, Venturini A, Ronzoni M, Saggiorato G, Simioni P, Zanon E. Advantages of FVIII-Extended Half-Life (Turoctocog Alfa Pegol) in the Management of Cardiac Surgery in a Patient with Mild Hemophilia A: A Case Report and Literature Review. Hematology Reports. 2025; 17(4):41. https://doi.org/10.3390/hematolrep17040041

Chicago/Turabian Style

Napolitano, Angela, Andrea Venturini, Mauro Ronzoni, Graziella Saggiorato, Paolo Simioni, and Ezio Zanon. 2025. "Advantages of FVIII-Extended Half-Life (Turoctocog Alfa Pegol) in the Management of Cardiac Surgery in a Patient with Mild Hemophilia A: A Case Report and Literature Review" Hematology Reports 17, no. 4: 41. https://doi.org/10.3390/hematolrep17040041

APA Style

Napolitano, A., Venturini, A., Ronzoni, M., Saggiorato, G., Simioni, P., & Zanon, E. (2025). Advantages of FVIII-Extended Half-Life (Turoctocog Alfa Pegol) in the Management of Cardiac Surgery in a Patient with Mild Hemophilia A: A Case Report and Literature Review. Hematology Reports, 17(4), 41. https://doi.org/10.3390/hematolrep17040041

Article Metrics

Back to TopTop